Decoy Therapeutics Inc. (DCOY) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Decoy Therapeutics Inc. (formerly Salarius Pharmaceuticals, Inc.) is a pre-clinical stage biotechnology company. In November 2025, the company completed a merger with Legacy Decoy Therapeutics and changed its name and ticker symbol to "DCOY" on January 8, 2026. The company focuses on peptide conjugate therapeutics via its IMP 3 ACT platform and small molecule drugs (SP-3164 and SP-2577). It has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,224,628) | $(1,709,533) |
| Operating Expenses | $2,283,739 | $1,718,695 |
| Cash & Equivalents (End of Period) | $7,820,608 | $1,798,380 |
| Restricted Cash | ~$3.0 million | ~$3.0 million |
| Working Capital | $3.8 million | Filing text does not provide a clear value |
| Stockholders' Equity | $3,877,385 | $61,866 |
Debt & Liquidity: The company has no long-term debt listed on the balance sheet. Current liabilities total $4.5 million, primarily consisting of deferred revenue ($3.2 million). The company reported a net cash outflow from operating activities of $2.9 million for the quarter.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by approximately $515,000 (30%) compared to Q1 2025, driven by higher operating expenses.
- R&D Expense Surge: Research and development expenses jumped from $75,532 in Q1 2025 to $749,813 in Q1 2026. This increase is attributed to the integration of the Legacy Decoy IMP 3 ACT (Designable Multi-Antivirals) program.
- Capital Position: Cash balances increased significantly from the prior year due to financing activities in late 2025 (merger-related), though cash decreased by $2.9 million during the current quarter due to operational burn.
- Stock Structure: The company effected a 1-for-12 reverse stock split effective March 6, 2026, and a 1-for-15 split in August 2025. Historical data has been recast to reflect these splits.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. They believe existing cash resources may not be sufficient to fund operations for one year from the issuance date. If additional capital is not secured, the company may be forced to cease operations.
- Regulatory Compliance: The company regained compliance with Nasdaq's minimum bid price requirement ($1.00) as of March 31, 2026, following a reverse stock split and an appeal process.
- Pipeline Strategy: The company plans to file an IND application for its IMP 3 ACT platform in the first half of 2027. The SP-2577 clinical trial at MD Anderson is no longer enrolling, and the company is seeking strategic alternatives (e.g., out-licensing) for this asset.
- Financing Needs: The company explicitly states it will need to raise additional capital to continue development. No equity sales occurred in Q1 2026.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash exhaustion and the status of any pending financing discussions, given the "substantial doubt" disclosure.
- Restricted Cash Usage: Confirm the specific milestones required to unlock the ~$3.0 million in Gates Foundation restricted cash, as this cannot be used for general administrative purposes.
- Nasdaq Compliance: Monitor the stock price to ensure continued compliance with Nasdaq listing rules following the recent reverse split.
- Merger Integration: Assess the progress of integrating Legacy Decoy's assets and the specific cost drivers behind the 9x increase in R&D expenses.
- Deferred Revenue Recognition: Review the terms of the $3.2 million deferred revenue to understand the timeline for recognizing this as income.